Harrow Launches "Harrow Access for All" to Broaden Affordable Eye Care Access Nationwide

Harrow has announced the launch of Harrow Access for All (HAFA), a new national initiative aimed at improving affordability and accessibility to its full portfolio of branded, generic, and compounded ophthalmic medications. The HAFA program builds on the success of Vevye Access for All (VAFA), a patient-first initiative introduced in March 2025 that focused exclusively on Vevye (cyclosporine ophthalmic solution) 0.1%, used to treat the signs and symptoms of dry eye disease.

According to Harrow, VAFA’s simplified access model led to a 66% increase in Vevye prescriptions during Q2 2025, underscoring the demand for patient-centric approaches in eye care. HAFA will now extend that model to the company’s broader ophthalmic offerings.

Key Features of the HAFA Program

Set to begin rolling out in late 2025, HAFA is designed to reduce both cost and administrative burden for prescribers and patients. According to Harrow, the program includes:

       • Affordability: Predictable, transparent pricing across branded, AGx (authorized generics), and compounded products.

       • Streamlined Prescribing: A unified platform that simplifies ordering and reduces administrative workload for clinicians.

       • Reliable Access: A consistent medication supply to support uninterrupted treatment and improved patient outcomes.

Mark L. Baum, Chief Executive Officer of Harrow, emphasized the company’s mission to eliminate access barriers:

“HAFA is designed to remove the financial and logistical obstacles that too often prevent patients from receiving timely access. Our goal is to ensure that every patient, regardless of insurance status or financial means, can access our sight-preserving medications without delay.”

Patient Affordability

Through HAFA, eligible commercially insured patients may pay as little as $0, while out-of-pocket costs are capped at $59 for all eligible patients, ensuring accessibility across a range of coverage statuses.

Three-Phase Implementation Plan

The HAFA program will be rolled out in three phases:

       • Phase 1 – Q4 2025 Launch: Will include Harrow’s core specialty products, such as the upcoming Byqlovi (clobetasol propionate ophthalmic suspension) 0.05%, with a patient cost range of $0 to $59.

       • Phase 2 – First Half of 2026: Will expand the program to include Harrow’s AGx portfolio, further improving patient access.

       • Phase 3 – 2027: HAFA will encompass all Harrow medications, including compounded alternatives. For uninsured patients, the program ensures treatment availability through AGx or cash-pay options.